Latest Publications

Share:

More Biotech and Diagnostic Patents At Risk After Federal Circuit Decision

On December 17, 2014, the Federal Circuit Court of Appeals found that certain claims relating to Myriad’s BRCA1 genetic test for breast and ovarian cancer were invalid under 35 U.S.C. § 101 as being ineligible for patent...more

FDA’s 'Purple Book' for Biologics—Patents Not Included

This past week, the Food and Drug Administration (FDA) announced the creation of the “Purple Book,” which will list all biological products, including any biosimilar and interchangeable biological products, licensed by the...more

Federal Circuit Clarifies Patent Term Adjustment Provisions

On January 15, 2014, the Federal Circuit issued in Novartis v. Lee its anticipated opinion regarding the proper interpretation of 35 U.S.C. § 154, the statute that determines how patent term adjustment (PTA) is calculated....more

Human Genes Are Not Patent Eligible Subject Matter

Today, the U.S. Supreme Court held that human genes are not patent eligible subject matter under 35 U.S.C. §101 simply because they have been isolated from the surrounding genetic material....more

Paying Your Dues ... Your Maintenance Fees Will Become Significantly More Expensive

The United States Patent and Trademark Office (USPTO) has recently published increases in maintenance fees that are effective on March 19, 2013. Careful attention to your maintenance fee schedule may provide a savings for...more

2/12/2013  /  Maintenance Fees , Patents , USPTO
5 Results
/
View per page
Page: of 1

"My best business intelligence,
in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!